InvoX Pharma to Extends Offer to Acquire F-star Therapeutics for USD 7.12/Share.

MANews-(C)2009-2022

UK-based pharmaceutical company invoX Pharma Ltd -star Therapeutics, Inc. has extended the expiration of its previously announced tender offer for all of the issued and outstanding common shares of UK-based clinical-stage biopharmaceutical company F-star (NASDAQ: FSTX) for USD 7.12 per share, the company said.

The tender offer is now scheduled to expire at 05:00 p.m., eastern time, on September 19, 2022, unless it is further extended. The tender offer was previously scheduled to expire at one minute after 11: 59 P.M., Eastern time, on August 3, 2022.

The tender offer is being extended in order to allow additional time for the satisfaction of the regulatory conditions to the offer.

The depositary for the tender offer has advised invoX that as of the previous expiration time there were validly tendered and not withdrawn a total of approximately 13,026,582 shares of F-star common stock, and approximately 2,704,867 shares of F-star common stock tendered pursuant...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT